Ensysce Biosciences, Inc.
ENSC
$2.11
$0.052.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 415.60% | 256.36% | 133.58% | 40.41% | -51.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 415.60% | 256.36% | 133.58% | 40.41% | -51.96% |
| Cost of Revenue | 58.36% | 26.72% | -4.85% | -52.11% | -59.87% |
| Gross Profit | 57.42% | 56.42% | 62.49% | 85.80% | 61.91% |
| SG&A Expenses | -8.89% | -8.18% | -11.95% | -0.67% | -6.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.71% | 11.34% | -7.79% | -36.55% | -45.09% |
| Operating Income | 31.17% | 31.45% | 37.21% | 54.16% | 43.89% |
| Income Before Tax | 41.65% | 40.99% | 24.83% | 37.08% | 42.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.65% | 40.99% | 24.83% | 37.08% | 42.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -91.30% | -100.00% | -99.24% | -- | -88.67% |
| Net Income | 41.64% | 40.95% | 24.74% | 37.09% | 42.88% |
| EBIT | 31.17% | 31.45% | 37.21% | 54.16% | 43.89% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 90.21% | 87.48% | 82.30% | 91.72% | 96.65% |
| Normalized Basic EPS | 90.20% | 87.47% | 82.73% | 91.25% | 97.06% |
| EPS Diluted | 90.21% | 87.48% | 82.30% | 91.72% | 96.65% |
| Normalized Diluted EPS | 90.20% | 87.47% | 82.73% | 91.25% | 97.06% |
| Average Basic Shares Outstanding | 298.02% | 310.92% | 350.24% | 309.45% | 445.81% |
| Average Diluted Shares Outstanding | 298.02% | 310.92% | 350.24% | 309.45% | 445.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |